Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.
Also called NCT06104423
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 266 participants
- Registry
-
NCT06104423 -
2022-003060-25
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Hungary
- Registry status
- Completed
Technical summary
Registry record NCT06104423. Non-randomized; no masking; primary purpose treatment. Start 2023-10-02 (actual); primary completion 2024-02-19 (actual). Results posted on 2025-04-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
- Acronym
- ARTEMISIA
- Condition
- Hypertension
- Intervention (Drug)
- Nebivolol 5 mg
- Intervention (Drug)
- Ramipril 2.5/5/10 mg
- Lead sponsor
- Menarini International Operations Luxembourg SA
Record details
- Record id
cardio:ct-nct06104423- Content hash
772f848278fefc0c438543149f1970d567acc20eb37fb828736910ace682b601